Ma Songjiang 4
4 · GYRE THERAPEUTICS, INC. · Filed May 14, 2025
Insider Transaction Report
Form 4
Ma Songjiang
DirectorPresident
Transactions
- Sale
Common Stock
2025-05-13$11.37/sh−2,000$22,740→ 2,820,844 total(indirect: By Spouse) - Sale
Common Stock
2025-05-12$10.56/sh−2,000$21,120→ 2,822,844 total(indirect: By Spouse)
Footnotes (3)
- [F1]This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024.
- [F2]The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.00 to $10.885. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- [F3]The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $11.16 to $11.69. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.